Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New flu vaccine shows promise in large trial

NCT ID NCT05569239

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a single dose of a new flu vaccine called OVX836 in about 2,850 healthy adults aged 18 to 59. The goal is to see if it can prevent confirmed influenza A and how safe it is. Participants will be randomly assigned to receive either the vaccine or a placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 2,850 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2025

Expected to finish

May 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 59 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Written informed consent 2. Healthy male or female subjects, as determined by medical history and medical examination. 3. Between the ages of 18 and 59 years, inclusive. 4. Subject socially active: living in a family with children or with other house-hold members, having frequent social contacts at university, work, in public places such as restaurants, theaters, public transportation, etc. 5. Subjects compliant with the reproductive criteria for male and female participants . 6. Reliable and willing to make themselves available for the duration of the study, and willing and able to follow study procedures 7. Able to read, understand and complete an electronic Diary and electronic Patient Reported Outcome. 8. Able to read and sign the subject information sheet and informed consent form (ICF). Exclusion Criteria: 1. Previous vaccination with an authorized or experimental seasonal, zoonotic or pandemic influenza vaccine within 6 months before the day of vaccination or planned to receive it during the whole study period. 2. Formal indication for influenza vaccination on an individual basis according to local recommendations, for example based on occupational risk, or underlying medical conditions. An informed subject who would refuse to get the regular influenza vaccination would be allowed to participate in this study. 3. Any known or suspected immunodeficient conditions. 4. Past or current history of significant autoimmune diseases, as judged by the Investigator. 5. Known or suspected infection with human immunodeficiency virus, hepatitis C virus, or hepatitis B virus. 6. Current history of significant uncontrolled medical illness such as diabetes, hypertension, heart, renal or hepatic diseases, as judged by the Investigator. 7. Planned absences without access to the investigational site, i.e. vacation or business trips, for more than 7 consecutive days during the study period 8. Pregnant or lactating woman. 9. Females planning to become pregnant or planning to discontinue contraceptive precautions until the end of the trial. 10. Having received another vaccine within 1 month prior to the day of study vaccination, except COVID-19 vaccines for which the minimum time period should be two weeks prior to study vaccination. 11. Having participated or currently participating in an OVX836 study or in the OVX-FLU-002 study. 12. Planning to receive any other vaccines during the first 28 days following the study vaccine administration, except COVID-19 vaccines which can be administered from 14 days following the study vaccine administration. 13. Administration of any investigational or non-registered drug or vaccine within 1 months prior to the administration of study vaccines, or planned administration of any such product during the whole study period. 14. History of receiving blood, blood components or immunoglobulins within 3 months prior to the day of vaccination, or planned to receive such product during the whole study period. 15. Presence of an acute febrile illness on the day of planned vaccination (oral temperature \>38.0°C; temporary exclusion criterion). 16Diagnosed long COVID-19 subjects. 17. Presence of a condition in the ear-nose-throat area, such as nasal septum deviation, atrophic rhinitis, etc…, that could render nasal and nasopharyngeal swabs more difficult to perform, or increase the risk of bleeding; to be confirmed by medical history question and inspection of nasal passage. 18\. Past or current history of any progressive or severe uncontrolled neurological disorder, seizure disorder or Guillain-Barré syndrome. 19\. Behavioral or cognitive impairment, or psychiatric disease that, in the opinion of the Investigator, may interfere with the subject's ability to participate in the study. 20\. Past (stopped less than 6 months before enrolment) or current smoking habit above 10 cigarettes per day. 21\. Past (stopped less than 6 months before enrolment) or current history of heavy alcohol use, defined as follows: for men, consumption of more than 4 standard drinks on any day or more than 14 standard drinks per week, and for women, consumption of more than 3 standard drinks on any day or more than 7 standard drinks per week. 22\. Past (stopped less than 6 months before enrolment) or current use of recreational drugs, which could interfere with the adherence to the protocol procedures. 23\. Chronic or prolonged treatment (\>10 consecutive days) that can affect immune response, such as systemic (≥ 20 mg/day prednisone or equivalent or dexamethasone \>4 mg/day), high dose inhaled corticosteroids (\>800 μg/day beclomethasone or equivalent; occasional inhaled, topical or localized injections \[intra-articular or intra-bursal\] of corticosteroids for asthma therapy are allowed), or immunomodulators/suppressors (certain monoclonal antibodies can be approved on a case by case basis) within 28 days before study entry or during the whole study duration. 24\. Chronic or prolonged (\>10 days) use of systemic non-steroidal anti-inflammatory drugs, acetylsalicylic acid, or paracetamol within 7 days before study entry and up to 28 days post-vaccination. 25\. Prophylactic or therapeutic use of influenza antivirals within 7 days prior to the day of study vaccination or during the whole study duration. 26\. History of severe allergic reactions and/or anaphylaxis, or serious adverse reactions to vaccines or allergy to kanamycin or any other component of the OVX836 vaccine. 27\. Any contraindication to intramuscular administration, as judged by the Investigator. 28\. Presence of extended tattoos on both deltoid muscles. 29. Individuals with history of any illness that, in the opinion of the Investigator, might interfere with the results of the study, or pose additional risk to the subjects due to participation in the study, either directly or through any treatments administered for that illness. 30\. Sponsor employees or Investigator site personnel directly affiliated with this study, and their immediate families. Immediate family is defined as a spouse (or assimilated), parent, child or sibling, whether biological or legally adopted.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Influenza are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • FI-14

    Kokkola, Finland

  • Site BE-01

    Ghent, Belgium

  • Site BE-02

    Antwerp, Belgium

  • Site BE-03

    Antwerp, Belgium

  • Site BE-04

    Mechelen, Belgium

  • Site DE-16

    München, Germany

  • Site FI-08

    Helsinki, Finland

  • Site FI-09

    Tampere, Finland

  • Site FI-10

    Turku, Finland

  • Site FI-11

    Oulu, Finland

  • Site FI-12

    Espoo, Finland

  • Site FI-13

    Jarvenpaa, Finland

  • Site FI-15

    Seinäjoki, Finland

  • Site FR-05

    Lyon, France

  • Site FR-06

    Rennes, France

  • Site FR-07

    Paris, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.